{
    "clinical_study": {
        "@rank": "141163", 
        "acronym": "CIK", 
        "arm_group": {
            "arm_group_label": "Decitabine", 
            "arm_group_type": "Experimental", 
            "description": "A continuous 5-day treatment of lower dose decitabine within 4-6 weeks is regarded as a treatment cycle, transfusion of auto-CIK cells or chemotherapy regimen may be used for patients."
        }, 
        "brief_summary": {
            "textblock": "Determine alone or in combination with chemotherapy or autologous cytokine induced killer\n      cells are effective and safe in the treatment of patients with relapsed and/or refractory\n      solid tumors or B Cell lymphomas."
        }, 
        "brief_title": "Lower Dose Decitabine Based Therapy in Patients With Refractory and/or Chemotherapy Resistant Solid Tumors or B Cell Lymphomas", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Solid Tumors", 
            "B Cell Lymphoma"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Lymphoma", 
                "Lymphoma, B-Cell", 
                "Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "The purpose of this study is to determine whether lower dose decitabine based therapy is\n      safe and can effectively control tumor progression."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Solid Tumor\n\n               -  Histologically confirmed advanced solid tumor\n\n               -  1 to 3 prior treatment regimens\n\n               -  At least one site of radiographically measurable disease of \u2265 2 cm in the\n                  largest dimension by traditional computerized tomography (CT) scanning technique\n                  or \u2265 1 cm in the largest dimension by spiral CT scanning (per RECIST criteria);\n                  or if, in the Principal Investigator's opinion, evaluable disease can be\n                  reliably and consistently followed, the subject may be eligible upon approval by\n                  the Medical Monitor\n\n          -  B Cell Lymphoma\n\n               -  Histologically or cytologically confirmed B Cell Lymphoma.\n\n               -  Patients must have had an initial diagnosis of B Cell NHL (including follicular,\n                  small lymphocytic, lymphoplasmacytoid, and marginal zone lymphoma), indolent\n                  disease that transformed to a more aggressive subtype, as previously described\n                  or patients may have mantle cell lymphoma.\n\n               -  Patients are required to have received prior chemotherapy (alone or combined\n                  with rituximab or other treatment) and are considered refractory to (defined as\n                  no response, or progression within 6 months of completing therapy) or intolerant\n                  of continued rituximab or other treatment.\n\n               -  Patients may have received up to a maximum of four prior unique chemotherapy\n                  regimens, including if not contra-indicated autologous stem-cell transplantation\n                  (ASCT).\n\n               -  For patients to enroll in the expanded dose group for lymphoma, patients must\n                  have measurable disease\n\n        Exclusion Criteria:\n\n          -  Disease Related\n\n               -  Chemotherapy with approved or investigational anticancer therapeutics, including\n                  steroid therapy, within 3 weeks prior to first dose or 6 weeks for antibody\n                  therapy\n\n               -  Radiation therapy or immunotherapy within 3 weeks prior to first dose (except\n                  for antibody therapy, where 6 weeks is required); localized radiation therapy\n                  within 1 week prior to first dose\n\n               -  Subjects with prior brain metastases are permitted, but must have completed\n                  treatment and have no evidence of active central nervous system (CNS) disease\n                  for at least 4 weeks prior to first dose\n\n               -  For lymphoma patients; patients with prior stem cell transplant therapy\n                  (autologous SCT within the prior 8 weeks; allogeneic SCT within the prior 16\n                  weeks). Patients with prior allogeneic SCT should not have evidence of\n                  moderate-to-severe GVHD.\n\n               -  Participation in an investigational therapeutic study within 3 weeks prior to\n                  first dose\n\n               -  Prior treatment with decitabine\n\n        Concurrent Conditions\n\n          -  Major surgery within 3 weeks prior to first dose\n\n          -  Congestive heart failure (New York Heart Association class III to IV), symptomatic\n             ischemia, conduction abnormalities uncontrolled by conventional intervention, or\n             myocardial infarction within 3 months prior to first dose\n\n          -  Acute active infection requiring systemic antibiotics, antivirals, or antifungals\n             within 2 weeks prior to first dose\n\n          -  Known or suspected HIV infection or subjects who are HIV seropositive\n\n          -  Active hepatitis A, B, or C infection\n\n          -  Significant neuropathy (Grade 3, Grade 4, or Grade 2 with pain) at the time of the\n             first dose\n\n        Ethical / Other\n\n          -  Female subjects who are pregnant or lactating\n\n          -  Any clinically significant psychiatric or medical condition that in the opinion of\n             the Investigator could interfere with protocol adherence or a subject's ability to\n             give informed consent"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "85 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 22, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01799083", 
            "org_study_id": "CHN-PLAGH-BT-002"
        }, 
        "intervention": [
            {
                "arm_group_label": "Decitabine", 
                "description": "A continuous 5-day lower-dose decitabine transfusion will be performed for patients during each treatment cycle, and autologous cytokine-induced killer cells may be transfused or chemotherapy may be also added.", 
                "intervention_name": "Decitabine", 
                "intervention_type": "Drug", 
                "other_name": "Dacogen"
            }, 
            {
                "arm_group_label": "Decitabine", 
                "description": "Autologous cytokine-induced killer cells may be used for patients before and after decitabine treatment.", 
                "intervention_name": "cytokine-induced killer cell", 
                "intervention_type": "Biological", 
                "other_name": "CIK transfusion"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Decitabine"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Advanced solid tumors", 
            "B cell lymphoma"
        ], 
        "lastchanged_date": "February 26, 2013", 
        "location": {
            "contact": {
                "email": "hanwdrsw@sina.com", 
                "last_name": "Wei D Han, Doctor", 
                "phone": "+86-10-66937463"
            }, 
            "contact_backup": {
                "email": "luxuechun@126.com", 
                "last_name": "Xue C Lu, Doctor", 
                "phone": "+86-10-66876237"
            }, 
            "facility": {
                "address": {
                    "city": "Beijing", 
                    "country": "China", 
                    "state": "Beijing", 
                    "zip": "100853"
                }, 
                "name": "Biotherapeutic Department of Chinese PLA General Hospital"
            }, 
            "investigator": [
                {
                    "last_name": "Yang Liu, Master", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Bo Yang, Doctor", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Yao Wang, Master", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Yan Zhang, Doctor", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Wei D Han, Doctor", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Xue C Lu, Doctor", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase 1/2 Study of Decitabine Alone and/or in Combination With Chemotherapy and/or Cytokine Induced Killer Cell Transfusion in Patients With Relapsed or Refractory Solid Tumors and B Cell Lymphomas", 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Chinese PLA General Hospital: China", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Response confirmed by non-investigational CT or MRI, or confirmed by biopsy", 
            "safety_issue": "Yes", 
            "time_frame": "within the first 30 days  after  four-cycle treatment"
        }, 
        "reference": [
            {
                "PMID": "21913005", 
                "citation": "Lu XC, Yang B, Yu RL, Chi XH, Tuo S, Tuo CW, Zhu HL, Wang Y, Jiang CG, Fu XB, Yang Y, Liu Y, Yao SQ, Dai HR, Cai L, Li BJ, Han WD. Clinical study of autologous cytokine-induced killer cells for the treatment of elderly patients with diffuse large B-cell lymphoma. Cell Biochem Biophys. 2012 Jan;62(1):257-65. doi: 10.1007/s12013-011-9273-6."
            }, 
            {
                "PMID": "22972689", 
                "citation": "Yang B, Lu XC, Yu RL, Chi XH, Liu Y, Wang Y, Dai HR, Zhu HL, Cai LL, Han WD. Repeated transfusions of autologous cytokine-induced killer cells for treatment of haematological malignancies in elderly patients: a pilot clinical trial. Hematol Oncol. 2012 Sep;30(3):115-22. doi: 10.1002/hon.1012. Epub 2011 Aug 23."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01799083"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Chinese PLA General Hospital", 
            "investigator_full_name": "Han weidong", 
            "investigator_title": "Researcher", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": {
            "measure": "tumor marker", 
            "safety_issue": "Yes", 
            "time_frame": "at least once within 30 days afther completing  four-cycle treatment"
        }, 
        "source": "Chinese PLA General Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Han weidong", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2013"
    }
}